Evidence map›Paper›PMID 42832300›Full record

ArticleThe oncologist2026

New prognosis indexes specific to Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma combining functional hepatic reserve and tumor burden.

Koji Fujita, Rie Yano, Mai Nakahara, Kyoko Oura, Hironobu Suto, Asahiro Morishita, Takashi Himoto, Keiichi Okano, Hideki Kobara

Abstract read
PubMed Publisher
In one paragraph

Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Koji FujitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan.ORCID 0000-0001-9390-7565
Rie YanoDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan.ORCID 0009-0001-4155-2376
Mai NakaharaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan.
Kyoko OuraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan.
Hironobu SutoDepartment of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan.
Asahiro MorishitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan.
Takashi HimotoDepartment of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu 761-0123, Japan.
Keiichi OkanoDepartment of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan.
Hideki KobaraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu 760-8521, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with Barcelona Clinic Liver Cancer stage B (BCLC-B) hepatocellular carcinoma (HCC) are characterized by heterogeneity in functional hepatic reserve and tumor burden. Conventional prognosis indexes are not specific to this stage. This study aimed to establish novel prognosis indexes that integrated functional hepatic reserve and tumor burden in patients with BCLC-B HCC.

methodsA total of 1843 patients with BCLC-B HCC were retrospectively enrolled from 4 hospitals. The primary endpoint was overall survival. Tumor burden was quantified as the biproduct or sum of the maximum diameter and the number of tumor nodules that is referred to as mMDN and mUS. Functional hepatic reserve was described using the albumin-bilirubin (ALBI) score.

resultsMultivariate analysis demonstrated that functional hepatic reserve and tumor burden were significantly associated with overall survival. Novel prognosis indexes, termed mMDN/ALBI and mUS/ALBI, were generated by dividing mMDN and mUS by the absolute value of the ALBI score. The mMDN/ALBI and mUS/ALBI models demonstrated superior prognostic stratification of overall survival compared with the ALBI and Tokyo scores, as reflected by higher log-rank trend chi-square statistics and C-index values. Time-dependent ROC and decision curve analyses further supported their superior predictive performance and clinical utility. mMDN/ALBI ≥ 8.2 indicated poor overall survival with a median survival time of 12 to 14 months whether functional hepatic reserve was preserved or not. mUS/ALBI ≥ 5.6 also suggested the median survival time of 9 to 12 months.

conclusionThe novel prognosis indexes stratified overall survival more clearly compared to the ALBI score and Tokyo score. These indexes enable more accurate prognosis prediction for patients with BCLC-B HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesTumor BurdenALBI gradeBarcelona Clinic Liver Cancer stagehepatocellular carcinomaTNM classification

Identifiers

PMID42832300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.